Remove Cardiology Remove Clinical Trials Remove Research
article thumbnail

Integrating Bioanalytical Automation, Biomarkers, Pharmacogenomics, & Cost-Effective Strategies

Worldwide Clinical Trials

Biomarkers are indispensable tools in clinical trials, providing critical insights that enhance the efficiency and precision of drug development. Our biomarker testing capabilities, offered across BioA and Clinical Pharmacology Unit (CPU) sites, provide a comprehensive and tailored approach to biomarker analysis.

article thumbnail

Grand Rounds December 15, 2023: Diversifying Clinical Trials: A Path Forward (Roxana Mehran, MD, FACC, FAHA, MSCAI, FESC)

Rethinking Clinical Trials

Yet enrollment of ethnic minorities in NIH clinical trials and for trials studying approved devices and drugs remains low. Increasing diversity in trial leadership is one of the most important strategies to increase diversity among RCT participants. CVD is the leading cause of mortality in women.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How the Ukrainian clinical trial industry is overcoming disruption

Pharmaceutical Technology

Clinical trials were thrown into turmoil on the morning of 24 February 2022, along with every aspect of life in Ukraine. In July, approximately a third of companies had paused a trial in the country. By August, 28 foreign-sponsored, multi-country trials were affected, almost half with sites in Ukraine and Russia. [1].

article thumbnail

Velocity Launches Cardiology Council to Accelerate Research Excellence (CARE)

Velocity Clinical Research

Velocity is proud to unveil another groundbreaking initiative: the Cardiology Council to Accelerate Research Excellence (CARE). The proliferation of heart issues — paired with patient lifestyle factors that complicate recruitment and study design — reflect an urgent need for expert-led clinical trials.

article thumbnail

January 17, 2024: In This Friday’s PCT Grand Rounds, Why Are Imaging Trials Different?

Rethinking Clinical Trials

Douglas is the Ursula Geller Professor of Research in Cardiovascular Diseases at Duke University and a past president of both the American College of Cardiology and the American Society of Echocardiography. The post January 17, 2024: In This Friday’s PCT Grand Rounds, Why Are Imaging Trials Different?

Trials 144
article thumbnail

June 12, 2024: Registry-Based DAPA-MI Trial to Be Featured in This Week’s PCT Grand Rounds

Rethinking Clinical Trials

James and Oldgren are professors of cardiology in the Department of Medical Sciences and the Uppsala Clinical Research Center at Uppsala University. The post June 12, 2024: Registry-Based DAPA-MI Trial to Be Featured in This Week’s PCT Grand Rounds appeared first on Rethinking Clinical Trials.

Trials 144
article thumbnail

Regulator and Funder? FDA’s Orphan Products Grants Program awards significant funding to help move promising treatments through clinical development

FDA Law Blog

Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field. In October, FDA announced seven new clinical trial grants awarded in fiscal year (FY) 2024 – including one for a Phase 3 trial – totaling $17.2